In-stent restenosis in the drug-eluting stent era

GD Dangas, BE Claessen, A Caixeta… - Journal of the American …, 2010 - jacc.org
The introduction of the drug-eluting stent (DES) proved to be an important step forward in
reducing rates of restenosis and target lesion revascularization after percutaneous coronary …

ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force …

SC Smith Jr, TE Feldman, JW Hirshfeld Jr… - Journal of the American …, 2006 - Elsevier
The ACC/AHA Task Force on Practice Guidelines was formed to gather information and
make recommendations about appropriate use of technology for the diagnosis and …

Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents

I Iakovou, T Schmidt, E Bonizzoni, L Ge, GM Sangiorgi… - Jama, 2005 - jamanetwork.com
ContextTraditionally, stent thrombosis has been regarded as a complication of percutaneous
coronary interventions during the first 30 postprocedural days. However, delayed …

Molecular basis of restenosis and drug-eluting stents

MA Costa, DI Simon - Circulation, 2005 - Am Heart Assoc
Next is a granulation or cellular proliferation phase. Growth factors are subsequently
released from platelets, leukocytes, and SMCs, which stimulate migration of SMCs from the …

ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention—summary article: a report of the American College of Cardiology/American Heart …

WRITING COMMITTEE MEMBERS, SC Smith Jr… - Circulation, 2006 - Am Heart Assoc
that support either the 2001 recommendations that have changed or the new or revised
recommendations are cited in parentheses at the end of each recommendation or comment …

Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus-or paclitaxel-eluting stents

AV Finn, FD Kolodgie, J Harnek, LJ Guerrero… - Circulation, 2005 - Am Heart Assoc
Background—Although effective coverage of challenging coronary lesions has warranted
the use of overlapping drug-eluting stents, the histopathological response to stent overlap is …

Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment

F Airoldi, A Colombo, N Morici, A Latib, J Cosgrave… - Circulation, 2007 - Am Heart Assoc
Background—The need for prolonged aspirin and thienopyridine therapy and the risk of
stent thrombosis (ST) remain as drawbacks associated with drug-eluting stents. Methods …

Early and mid-term results of drug-eluting stent implantation in unprotected left main

A Chieffo, G Stankovic, E Bonizzoni, E Tsagalou… - Circulation, 2005 - Am Heart Assoc
Background—The safety and efficacy of percutaneous coronary intervention in unprotected
left main (ULM) coronary arteries are still a matter of debate. Methods and Results—All …

Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation

MK Hong, GS Mintz, CW Lee, DW Park… - European heart …, 2006 - academic.oup.com
Aims In many countries, drug-eluting stent implantation is the dominant interventional
strategy. We evaluated the clinical, angiographic, procedural, and intravascular ultrasound …

Percutaneous treatment with drug-eluting stent implantation versus bypass surgery for unprotected left main stenosis: a single-center experience

A Chieffo, N Morici, F Maisano, E Bonizzoni… - Circulation, 2006 - Am Heart Assoc
Background—Improvements in results with percutaneous coronary intervention (PCI) with
drug-eluting stents (DES) may extend their use in patients with left main coronary artery …